The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia

Author(s):
Vojdeman, F.J.; van't Veer, M.B.; Tjonnfjord, G.E.; Itala-Remes, M.; Kimby, E.; Polliack, A.; Wu, K.L.; Doorduijn, J.K.; Alemayehu, W.G.; Wittebol, S.; Kozak, T.; Walewski, J.; Abrahamse-Testroote, M.C.J.; Oers, M.H.J. van; Geisler, C.H.
Published
2017
Publication type
Article / Letter to editor
CLLalemtuzumabchemo-immunotherapyelderlycomorbidityperformance status
Date issued
2017-12-31
Language
English
Is part of
Leukemia & Lymphoma (2017), Vol. 58, no. 3, p. 594-600
hdl
1887/115118
doi
10.1080/10428194.2016.1213831